Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway
Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.
How this was made
The 30-second read
Why it matters
The CMS national coverage eligibility milestone and first US patient enrollment/treatment are execution catalysts for the pivotal program. The update also notes ongoing international recruitment and additional regulatory clearances, while cash outflows remain elevated due to trial, regulatory, and manufacturing requirements.
Market read
Traders may re-rate AVR on improved pivotal trial execution odds after CMS reimbursement eligibility enabled US enrollment to begin, though financing/cash burn remains a key counterweight.
What to watch
The article highlights net operating cash outflows of $20.8M for the quarter, so dilution or financing risk may dominate near-term price action despite trial progress.
Background
Anteris is running the pivotal PARADIGM randomized trial for its DurAVR transcatheter heart valve in aortic stenosis, with enrollment dependent on site readiness and US reimbursement coverage.
Ticker impact
Anteris says it secured CMS reimbursement eligibility for the PARADIGM Trial and started enrolling and treating first US patients in May 2026.
Near-term upside bias as traders price improved trial execution odds; magnitude likely capped by ongoing cash burn and still-early site ramp.
The article discloses a concrete regulatory/reimbursement milestone plus first US patient treatment, both directly tied to trial progress. However, it provides no efficacy readout and only general next steps, while cash outflows remain substantial.
Market effects
Structural heart device peers may see read-across interest if CMS coverage frameworks appear to de-risk pivotal trial enrollment for competing THV platforms.
US trial execution progress can shift sentiment toward US-listed structural heart names with similar reimbursement-dependent enrollment dynamics.
International recruitment expansion (Denmark, Netherlands) and regulatory clearances (Canada, France) reinforce global trial continuity, which can modestly improve sector risk perception.
Counterpoint
Reimbursement eligibility does not guarantee rapid enrollment; site start-up timelines, screening rates, and patient flow could still lag expectations.
Key entities
- companyAnteris Technologies
Develops DurAVR transcatheter heart valve and is advancing the pivotal PARADIGM Trial.
- clinical_programPARADIGM Trial
Prospective randomized study comparing DurAVR against commercially available transcatheter aortic valve replacements.
- regulatoryCMS national coverage policy
US Centers for Medicare & Medicaid Services coverage eligibility for qualifying PARADIGM procedures.
- productDurAVR Transcatheter Heart Valve
Balloon-expandable THV using ADAPT anti-calcification tissue technology.
